Hereditary Angioedema Market

Market Overview:

The 7 major Hereditary Angioedema markets reached a value of US$ 1.8 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 3.5 Billion by 2034, exhibiting a growth rate (CAGR) of 6.1% during 2024-2034.

Hereditary Angioedema Market is currently witnessing strong growth driven by advances in identifying mechanisms of angioedema and developing modern safe and effective drugs to treat the disease. Furthermore, increasing global accessibility of advanced diagnostic tools and medications and improving drug development times have also created a positive impact on the market. Hereditary angioedema, or HAE, refers to a rare genetic disorder that is caused by dysfunctional or lack of C1-inhibitor protein. This condition is inherited in an autosomal dominant pattern, implying one copy of the altered gene in each cell is enough to cause the indication. It is characterized by recurrent episodes of rapid, severe, subcutaneous, and submucosal swelling of the face, hands, airways, intestinal tract, trachea, larynx, or tongue without the appearance of urticarial lesions. Hereditary angioedema affects the blood vessels and leads to extreme pain, nausea, vomiting, fatigue, diarrhea, muscle ache, tingling, headache, abdominal pain, hoarseness, and mood swings. It also results in fluid leakage through the walls of blood vessels into body tissues. Hereditary angioedema (HAE) affects around 1 in 50,000 of the population and does not show ethnic variation in frequency. Similar to other rare conditions, there is often a delay to diagnosis the indication, resulting in patients not receiving appropriate treatment at the right time.

IMARC Group’s new report "Hereditary Angioedema Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2034". provides an exhaustive analysis of the Hereditary Angioedema market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The report provides an in-depth understanding of current and future landscape of the Hereditary Angioedema market. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool for Hereditary Angioedema across the seven major markets. According to the report, among the seven major markets, the United States has the largest patient pool for Hereditary Angioedema and also represents the largest market for Hereditary Angioedema treatment. Furthermore, the current Hereditary Angioedema treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Hereditary Angioedema market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, Current and Future Epidemiology Scenario
• Historical, Current and Future Performance of the Hereditary Angioedema Market
• Historical, Current and Future Performance of Various Therapeutic Categories in the Hereditary Angioedema Market
• Sales of Various Drugs Across the Hereditary Angioedema Market
• Reimbursement Scenario in the Hereditary Angioedema Market

Competitive Landscape:

This report also provides a detailed analysis of the current Hereditary Angioedema marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

• How has the Hereditary Angioedema market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to be in 2034?
• What was the country-wise size of the Hereditary Angioedema market across the seven major markets in 2023 and how will it look like in 2034?
• What is the growth rate of the Hereditary Angioedema market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the Hereditary Angioedema market?

Epidemiology Insights

• What is the size of the Hereditary Angioedema patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) of Hereditary Angioedema across the seven major markets?
• What are the key factors driving the epidemiological trend of Hereditary Angioedema?
• What will be the growth rate of Hereditary Angioedema patients across the seven major markets?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed Hereditary Angioedema drugs and what are their market performance?
• What are the key pipeline Hereditary Angioedema drugs and how are they expected to perform in the coming years?
• How safe are the current marketed Hereditary Angioedema drugs and what are their efficacies?
• How safe are the late-stage pipeline Hereditary Angioedema drugs and what are their efficacies?
• What are the current treatment guidelines for Hereditary Angioedema drugs across the seven major markets?
• Who are the key companies in the Hereditary Angioedema market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Hereditary Angioedema market?